Liquid Biopsy Market - Global Forecast to 2030
商品番号 : SMB-9385
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年8月 |
| ページ数 | 393 |
| 図表数 | 546 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
リキッドバイオプシー市場は2025年の40億3,000万米ドル規模となり、予測期間中に年平均成長率（CAGR）11.8%で成長し、2030年には70億5,000万米ドルに達するとMarketsandMarketsでは予測しています。リキッドバイオプシーは、従来の生検法に比べて、非侵襲性、処置コストの低さ、より簡便な病状進行のモニタリング、そしてがんの早期発見の可能性など、いくつかの重要な利点を備えています。これらの利点は、エンドユーザーの間でリキッドバイオプシーの普及拡大に貢献しています。その結果、リキッドバイオプシーの臨床的価値に対する採用と認知度の向上が、予測期間中の市場成長を促進することが期待されています。
MarketsandMarkets（マーケッツアンドマーケッツ）「リキッドバイオプシー市場 – 製品とサービス（キット、機器）、循環バイオマーカー（ctDNA、cfDNA、CTC）、テクノロジー（NGS、PCR）、用途（肺がん、乳がん、前立腺がん）、サンプルタイプ（血液、尿、脳脊髄液）、エンドユーザー（病院） – 2030年までの世界予測 – Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (ctDNA, cfDNA, CTC), Technology (NGS, PCR), Application (Lung, Breast, Prostate Cancer), Sample Type (Blood, Urine, CSF), End User (Hospitals) – Global Forecast to 2030」は世界のリキッドバイオプシー（液体生検）市場を調査し、主要セグメント別に分析・予測を行っています。
調査対象セグメント
- 製品＆サービス
- 測定キット
- 器具
- サービス
- 循環バイオマーカー
- 循環腫瘍DNA（ctDNA）
- 無細胞DNA（セルフリー細胞）
- 循環腫瘍細胞
- 細胞外小胞
- その他の循環バイオマーカー
- 技術
- 次世代シーケンシング（NGS）を用いた多重遺伝子の並行分析
- PCRマイクロアレイを用いた単一遺伝子分析
- 用途
- がん
- 肺がん
- 乳がん
- 大腸がん
- 前立腺がん
- 悪性黒色腫（メラノーマ）
- その他のがん
- がん以外の用途
- 非侵襲性出生前検査
- 感染症検査
- がん
- サンプルタイプ
- 血液サンプル
- その他のサンプルタイプ
- エンドユーザ
- 参考検査室
- 病院内＆医師用検査室
- 学術研究センター
- その他のエンドユーザ
- 地域
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- その他の欧州
- アジア太平洋地域
- 中国
- 日本
- インド
- その他のアジア太平洋地域
- ラテンアメリカ
- ブラジル
- メキシコ
- その他のラテンアメリカ
- 中東＆アフリカ
- 北米
当レポートは製品およびサービス（アッセイキット、機器、サービス）、循環バイオマーカーの種類（循環腫瘍細胞、循環腫瘍DNA、遊離DNA、細胞外小胞、その他の循環バイオマーカー）、技術（NGSを使用したマルチ遺伝子並行解析およびPCRおよびマイクロアレイを使用した単一遺伝子解析）、用途（がん用途（肺がん、乳がん、大腸がん、前立腺がん、黒色腫、その他のがん）および非がん用途（非侵襲性出生前検査、臓器移植、感染症検査）、臨床用途（早期がんスクリーニング、治療法選択、治療モニタリング、再発モニタリング）、サンプルタイプ（血液およびその他のサンプルタイプ）、エンドユーザー（基準検査機関、病院および医師の検査室、学術研究センター、その他のエンドユーザー）、および地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東およびアフリカ）別に分類しています。本レポートは、リキッドバイオプシー市場の成長に影響を与える推進要因、制約要因、機会、課題といった主要要因に関する詳細な情報を網羅しています。主要業界プレーヤーの徹底的な分析により、各社の事業概要、ソリューション、主要戦略、買収・契約に関する洞察が得られています。リキッドバイオプシー市場に関連する新製品の発売や最近の動向についても解説しています。本レポートは、リキッドバイオプシー市場エコシステムにおける新興企業の競合分析も網羅しています。
Report Overview
The liquid biopsy market is projected to reach USD 7.05 billion by 2030 from USD 4.03 billion in 2025, at a CAGR of 11.8% during the forecast period. Liquid biopsy offers several key advantages over traditional biopsy methods, including its non-invasive nature, lower procedural costs, the ability to monitor disease progression more easily, and the potential for detecting cancer at early stages. These benefits have contributed to growing acceptance among end users. As a result, the increasing adoption and recognition of liquid biopsy’s clinical value are expected to fuel market growth during the forecast period.
By clinical application, the early cancer screening segment is expected to grow at the highest CAGR during the forecast period.
The liquid biopsy market is segmented by clinical application into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The early cancer screening segment is projected to register the highest CAGR during the forecast period. The high growth rate of this segment is driven by the rising incidence of cancer, the increasing importance of early disease diagnosis, and the development of effective oncology therapeutics for treatment. Rising research efforts & funding dedicated to early detection are accelerating the development of liquid biopsy technologies.
By sample type, the blood sample segment accounted for the largest market share in 2024.
Based on sample type, the liquid biopsy market is segmented into blood and other sample types. In 2024, the blood sample segment accounted for the largest share of the market. The large share of this segment is attributed to the ease of collection, minimal invasiveness, and its ability to provide comprehensive molecular insights from circulating biomarkers such as ctDNA, cfDNA, and CTCs. Blood-based sampling is safer, quicker, and more acceptable to patients than tissue biopsies, which has led to its widespread adoption in both research and diagnostics.
By region, the Asia Pacific is projected to grow at the highest CAGR during the forecast period.
The market is segmented by region into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The high growth rate of this market is driven by the increasing prevalence of cancer, the rising healthcare expenditure, expanding access to advanced diagnostics, and the growing presence of international & local diagnostic companies. Additionally, supportive government initiatives for cancer screening programs and rising awareness of non-invasive diagnostic options are expected to contribute to market growth.
The break-up of the profile of primary participants in the liquid biopsy market:
- By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
- By Designation: C-level – 27%, D-level – 18%, and Others – 55%
- By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and the Middle East & Africa- 4%
The key players in this market are Natera, Inc. (US), Guardant Health (US), Myriad Genetics, Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), Sysmex Corporation (Japan), maxhealth (US), Personalis, Inc. (US), GRAIL, Inc. (US), Menarini-Silicon Biosystems (Italy), NeoGenomics. Laboratories (US), ANGLE plc (UK), Vortex Biotech Holdings (US), Bio-Techne (US), MedGenome (US), Mesa Labs, Inc. (US), Labcorp, Holdings Inc (US), Freenome, Holdings, Inc. (US), Strand (India), LungLife Al, Inc. (US), Lucence Health Inc. (US), and New Day Diagnostics, LLC (US).
Research Coverage:
This research report categorizes the liquid biopsy market by product & service (assay kits, instruments, and services), circulating biomarker type (circulating tumor cells, circulating tumor DNA, cell-free DNA, extracellular vesicles, and other circulating biomarkers), technology (multi-gene parallel analysis using NGS and single-gene analysis using PCR & microarrays), application [cancer applications (lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, and other cancers) and non-cancer applications (non-invasive prenatal testing, organ transplantation, and infectious disease testing]), clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring), sample type (blood and other sample types), end user (reference laboratories, hospitals & physician laboratories, academic & research centers, and other end users), and region (North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa). The report’s scope covers detailed information regarding the leading factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the liquid biopsy market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product launches and recent developments associated with the liquid biopsy market. This report covers a competitive analysis of upcoming startups in the liquid biopsy market ecosystem.
Reasons to buy this report:
The report will help market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall liquid biopsy market and the subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (Rising incidence and prevalence of cancer, cancer awareness initiatives undertaken by global health organizations, and increased benefits of liquid biopsy over traditional biopsy procedures), opportunities (Growing significance of companion diagnostics and growth opportunities in emerging countries), restraints (Lower sensitivity of specific liquid biopsy procedures), and challenges (Unclear reimbursement scenario) influencing the growth of the liquid biopsy market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the liquid biopsy market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the liquid biopsy market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the liquid biopsy market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Natera, Inc. (US), Guardant Health (US), Myriad Genetics, Inc. (US), Illumina, Inc. (US), and F. Hoffmann-La Roche Ltd. (Switzerland).
Table of Contents
1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.3 MARKET SCOPE 36
1.3.1 MARKETS COVERED & REGIONAL SCOPE 36
1.3.2 INCLUSIONS & EXCLUSIONS 37
1.3.3 YEARS CONSIDERED 38
1.3.4 CURRENCY CONSIDERED 38
1.4 KEY STAKEHOLDERS 38
1.5 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
2.2 RESEARCH APPROACH 40
2.2.1 SECONDARY DATA 41
2.2.1.1 Key secondary sources 41
2.2.1.2 Key data from secondary sources 41
2.2.2 PRIMARY DATA 42
2.2.2.1 Primary sources 43
2.2.2.2 Key data from primary sources 43
2.2.2.3 Key industry insights 45
2.2.2.4 Breakdown of primary interviews 45
2.3 MARKET SIZE ESTIMATION 46
2.3.1 BOTTOM-UP APPROACH 47
2.3.1.1 Approach 1: Company revenue estimation approach 47
2.3.1.2 Approach 2: Presentations of companies and primary interviews 47
2.3.1.3 Growth forecast 48
2.3.1.4 CAGR projections 48
2.3.2 TOP-DOWN APPROACH 48
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 50
2.5 MARKET SHARE ASSESSMENT 50
2.6 RESEARCH ASSUMPTIONS 51
2.6.1 PARAMETRIC ASSUMPTIONS 51
2.7 RESEARCH LIMITATIONS 51
2.8 RISK ASSESSMENT 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHTS 59
4.1 LIQUID BIOPSY MARKET OVERVIEW 59
4.2 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION) 60
4.3 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2025 VS. 2030 (USD MILLION) 60
4.4 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 61
4.5 LIQUID BIOPSY MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 61
4.6 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION) 62
4.7 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION) 62
4.8 LIQUID BIOPSY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 63
4.9 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63
5 MARKET OVERVIEW 64
5.1 INTRODUCTION 64
5.2 MARKET DYNAMICS 64
5.2.1 DRIVERS 65
5.2.1.1 Increasing burden of cancer 65
5.2.1.2 Cancer awareness initiatives undertaken by
global health organizations 66
5.2.1.3 Expanding benefits of liquid biopsy over traditional biopsy procedures 67
5.2.2 RESTRAINTS 68
5.2.2.1 Lower sensitivity of specific liquid biopsy procedures 68
5.2.3 OPPORTUNITIES 69
5.2.3.1 Growing significance of companion diagnostics 69
5.2.3.2 Growth potential of emerging economies 69
5.2.4 CHALLENGES 70
5.2.4.1 Unfavorable reimbursement scenario 70
5.3 PRICING ANALYSIS 70
5.3.1 INDICATIVE SELLING PRICE TREND OF LIQUID BIOPSY PRODUCTS, 2023−2025 71
5.3.2 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023−2025 71
5.3.3 INDICATIVE SELLING PRICE TREND OF LIQUID BIOPSY PRODUCTS,
BY REGION, 2023−2025 72
5.4 PATENT ANALYSIS 73
5.4.1 LIST OF MAJOR PATENTS 74
5.5 VALUE CHAIN ANALYSIS 75
5.6 SUPPLY CHAIN ANALYSIS 77
5.7 TRADE ANALYSIS 78
5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS 78
5.7.2 IMPORT DATA (HS CODE 3822) 78
5.7.3 EXPORT DATA (HS CODE 3822) 79
5.8 ECOSYSTEM ANALYSIS 79
5.9 PORTER’S FIVE FORCES ANALYSIS 81
5.9.1 THREAT OF NEW ENTRANTS 82
5.9.2 THREAT OF SUBSTITUTES 82
5.9.3 BARGAINING POWER OF BUYERS 82
5.9.4 BARGAINING POWER OF SUPPLIERS 82
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 82
5.10 REGULATORY LANDSCAPE 83
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
5.10.2 NORTH AMERICA 84
5.10.2.1 US 84
5.10.2.2 Canada 85
5.10.3 EUROPE 85
5.10.4 ASIA PACIFIC 86
5.10.4.1 China 86
5.10.4.2 Japan 86
5.10.4.3 India 86
5.10.5 LATIN AMERICA 87
5.10.5.1 Brazil 87
5.10.5.2 Mexico 87
5.10.6 MIDDLE EAST 87
5.10.6.1 Africa 88
5.11 TECHNOLOGY ANALYSIS 88
5.11.1 KEY TECHNOLOGIES 88
5.11.1.1 Digital Droplet PCR (ddPCR) 88
5.11.1.2 Tagged-amplicon Deep Sequencing (TAm-Seq) 88
5.11.2 COMPLEMENTARY TECHNOLOGIES 88
5.11.2.1 Electrochemical biosensing technology 88
5.11.3 ADJACENT TECHNOLOGIES 89
5.11.3.1 Microfluidic-based devices 89
5.12 KEY CONFERENCES & EVENTS, 2025–2026 89
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 90
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 91
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 92
5.14.2 BUYING CRITERIA 92
5.15 INVESTMENT & FUNDING SCENARIO 93
5.16 CASE STUDY ANALYSIS 94
5.16.1 CASE STUDY 1: DETECTION OF LOW-FREQUENCY MUTATIONS USING TARGET SELECTOR CTDNA TECHNOLOGY 94
5.16.2 CASE STUDY 2: ANALYTICAL ASSESSMENT OF PLASMA & SERUM FOR CTDNA MUTATION DETECTION 94
5.17 IMPACT OF AI/GENERATIVE AI ON LIQUID BIOPSY MARKET 95
5.17.1 INTRODUCTION 95
5.17.2 MARKET POTENTIAL OF AI 95
5.17.3 AI USE CASES 96
5.17.4 FUTURE OF AI IN LIQUID BIOPSY MARKET 97
5.18 TRUMP TARIFF IMPACT ON LIQUID BIOPSY MARKET 97
5.18.1 INTRODUCTION 97
5.18.2 KEY TARIFF RATES 97
5.18.3 PRICE IMPACT ANALYSIS 98
5.18.4 KEY IMPACT ON COUNTRY/REGION 98
5.18.4.1 North America 98
5.18.4.2 Europe 99
5.18.4.3 Asia Pacific 99
5.18.5 IMPACT ON END-USE INDUSTRIES 99
5.18.5.1 Reference laboratories 99
5.18.5.2 Hospitals & physicians’ laboratories 99
5.18.5.3 Academic & research centers 99
6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE 100
6.1 INTRODUCTION 101
6.2 ASSAY KITS 101
6.2.1 RECURRING PURCHASE TO PROPEL MARKET 101
6.3 INSTRUMENTS 105
6.3.1 RISING TECHNOLOGICAL ADVANCES IN DDPCR TO FUEL MARKET 105
6.4 SERVICES 108
6.4.1 ADOPTION OF CFDNA & CTC TESTING SERVICES TO
SUPPORT MARKET GROWTH 108
7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE 111
7.1 INTRODUCTION 112
7.2 CIRCULATING TUMOR DNA 112
7.2.1 HIGH SENSITIVITY & SPECIFICITY TO PROPEL MARKET 112
7.3 CELL-FREE DNA 116
7.3.1 BROADENING APPLICATIONS IN PRENATAL SCREENING TO DRIVE MARKET 116
7.4 CIRCULATING TUMOR CELLS 119
7.4.1 EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF TUMORS TO FUEL MARKET 119
7.5 EXTRACELLULAR VESICLES 122
7.5.1 HIGH STABILITY IN BLOOD CIRCULATION TO ENSURE CONSISTENT GROWTH 122
7.6 OTHER CIRCULATING BIOMARKERS 124
8 LIQUID BIOPSY MARKET, BY TECHNOLOGY 128
8.1 INTRODUCTION 129
8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS 129
8.2.1 HIGHER THROUGHPUT EFFICIENCY TO PROPEL MARKET 129
8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS 132
8.3.1 COST-EFFICIENCY AND EASE OF USE TO FUEL UPTAKE 132
9 LIQUID BIOPSY MARKET, BY APPLICATION 136
9.1 INTRODUCTION 137
9.2 CANCER APPLICATIONS 137
9.2.1 LUNG CANCER 141
9.2.1.1 Growing prevalence of lung cancer to propel market 141
9.2.2 BREAST CANCER 144
9.2.2.1 Increasing funding investments for breast cancer research to drive market 144
9.2.3 COLORECTAL CANCER 148
9.2.3.1 Rising geriatric population to fuel uptake 148
9.2.4 PROSTATE CANCER 151
9.2.4.1 Adoption of tumor cell kits to boost demand 151
9.2.5 MELANOMA 154
9.2.5.1 Growing need for early diagnosis of genetically mutated tumors to drive market 154
9.2.6 OTHER CANCERS 157
9.3 NON-CANCER APPLICATIONS 160
9.3.1 NON-INVASIVE PRENATAL TESTING 163
9.3.1.1 Growing demand for NIPT in high-risk pregnancies to drive market 163
9.3.2 ORGAN TRANSPLANTATION 166
9.3.2.1 Early disease diagnosis & detection to support market growth 166
9.3.3 INFECTIOUS DISEASE TESTING 168
9.3.3.1 Potential accuracy & efficacy for testing to fuel uptake 168
10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION 171
10.1 INTRODUCTION 172
10.2 THERAPY SELECTION 172
10.2.1 GROWING PREFERENCE FOR PERSONALIZED TREATMENT TO DRIVE MARKET 172
10.3 TREATMENT MONITORING 175
10.3.1 EARLY DETECTION OF DISEASE PROGRESSION TO BOOST DEMAND 175
10.4 EARLY CANCER SCREENING 177
10.4.1 GROWING INCIDENCE OF CANCER AND RISING FUNDING INVESTMENTS TO PROPEL MARKET 177
10.5 RECURRENCE MONITORING 180
10.5.1 RISING NEED FOR POST-TREATMENT SURVEILLANCE TO FUEL UPTAKE 180
11 LIQUID BIOPSY MARKET, BY SAMPLE TYPE 183
11.1 INTRODUCTION 184
11.2 BLOOD SAMPLES 185
11.2.1 STANDARD SIMPLICITY AND HIGH PATIENT ACCEPTANCE TO PROPEL MARKET 185
11.3 OTHER SAMPLE TYPES 188
12 LIQUID BIOPSY MARKET, BY END USER 191
12.1 INTRODUCTION 192
12.2 REFERENCE LABORATORIES 192
12.2.1 RISING OUTSOURCING OF TESTS AND ABILITY TO UNDERTAKE LARGE SAMPLE VOLUMES TO PROPEL MARKET 192
12.3 HOSPITALS & PHYSICIANS LABORATORIES 195
12.3.1 INCREASING ESTABLISHMENT OF HOSPITALS TO BOOST DEMAND 195
12.4 ACADEMIC & RESEARCH CENTERS 198
12.4.1 INCREASING R&D ACTIVITIES FOR INNOVATIVE TESTS TO SUPPORT MARKET GROWTH 198
12.5 OTHER END USERS 201
13 LIQUID BIOPSY MARKET, BY REGION 204
13.1 INTRODUCTION 205
13.2 NORTH AMERICA 205
13.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 206
13.2.2 US 211
13.2.2.1 High healthcare expenditure to propel market 211
13.2.3 CANADA 215
13.2.3.1 Availability of various cancer screening programs to drive market 215
13.3 EUROPE 220
13.3.1 EUROPE: MACROECONOMIC OUTLOOK 220
13.3.2 GERMANY 225
13.3.2.1 Favorable research funding investments for cancer research to fuel market 225
13.3.3 UK 229
13.3.3.1 NHS-funded lab-based disease screening facilities to boost demand 229
13.3.4 FRANCE 233
13.3.4.1 Growing focus on expanding access to advanced genomic technologies to drive market 233
13.3.5 ITALY 237
13.3.5.1 Development of novel circulating cancer biomarkers to support market growth 237
13.3.6 SPAIN 241
13.3.6.1 Focus on personalized medicine to support market uptake 241
13.3.7 REST OF EUROPE 245
13.4 ASIA PACIFIC 249
13.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 249
13.4.2 CHINA 254
13.4.2.1 Increasing incidence of infectious diseases to propel market 254
13.4.3 JAPAN 258
13.4.3.1 Universal healthcare reimbursement policy to fuel market 258
13.4.4 INDIA 262
13.4.4.1 Increasing incidence of chronic diseases and growing focus on early disease diagnosis to drive market 262
13.4.5 REST OF ASIA PACIFIC 266
13.5 LATIN AMERICA 270
13.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 271
13.5.2 BRAZIL 275
13.5.2.1 Improvements in laboratory infrastructure to drive market 275
13.5.3 MEXICO 279
13.5.3.1 Improving accessibility to advanced healthcare services to support market growth 279
13.5.4 REST OF LATIN AMERICA 283
13.6 MIDDLE EAST & AFRICA 287
13.6.1 INCREASING COLLABORATIONS & DEVELOPMENTS FOR ENHANCED DIAGNOSTIC ACCESS TO SUPPORT MARKET GROWTH 287
13.6.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 287
14 COMPETITIVE LANDSCAPE 292
14.1 INTRODUCTION 292
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 292
14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN LIQUID BIOPSY MARKET 292
14.3 REVENUE ANALYSIS, 2022−2024 294
14.4 MARKET SHARE ANALYSIS 295
14.4.1 LIQUID BIOPSY MARKET 295
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 297
14.5.1 STARS 297
14.5.2 EMERGING LEADERS 297
14.5.3 PERVASIVE PLAYERS 297
14.5.4 PARTICIPANTS 297
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 299
14.5.5.1 Company footprint 299
14.5.5.2 Region footprint 300
14.5.5.3 Product & Service footprint 300
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES 301
14.6.1 PROGRESSIVE COMPANIES 301
14.6.2 RESPONSIVE COMPANIES 301
14.6.3 DYNAMIC COMPANIES 301
14.6.4 STARTING BLOCKS 302
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 303
14.6.5.1 Detailed list of key startups/SMEs 303
14.6.5.2 Competitive benchmarking of key startups/SMEs, by product & service 303
14.6.5.3 Competitive benchmarking of key startups/SMEs, by region 304
14.7 COMPANY VALUATION & FINANCIAL METRICS 305
14.7.1 FINANCIAL METRICS 305
14.7.2 COMPANY VALUATION 305
14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 306
14.8.1 BRAND COMPARISON OF PCR-BASED LIQUID BIOPSY ASSAYS 306
14.8.1.1 QIAGEN N.V. 306
14.8.1.2 Thermo Fisher Scientific Inc. 307
14.8.1.3 Bio-Rad Laboratories, Inc. 307
14.9 COMPETITIVE SCENARIO 307
14.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 307
14.9.2 DEALS 308
14.9.3 EXPANSIONS 309
15 COMPANY PROFILES 311
15.1 KEY PLAYERS 311
15.1.1 NATERA, INC. 311
15.1.1.1 Business overview 311
15.1.1.2 Products/Services offered 312
15.1.1.3 Recent developments 313
15.1.1.3.1 Product/Service launches 313
15.1.1.3.2 Deals 314
15.1.1.3.3 Other developments 314
15.1.1.4 MnM view 314
15.1.1.4.1 Key strengths 314
15.1.1.4.2 Strategic choices 314
15.1.1.4.3 Weaknesses & competitive threats 315
15.1.2 GUARDANT HEALTH 316
15.1.2.1 Business overview 316
15.1.2.2 Products/Services offered 317
15.1.2.3 Recent developments 318
15.1.2.3.1 Product/Service launches & approvals 318
15.1.2.3.2 Deals 320
15.1.2.4 MnM view 322
15.1.2.4.1 Key strengths 322
15.1.2.4.2 Strategic choices 322
15.1.2.4.3 Weaknesses & competitive threats 322
15.1.3 MYRIAD GENETICS, INC. 323
15.1.3.1 Business overview 323
15.1.3.2 Products/Services offered 324
15.1.3.3 Recent developments 325
15.1.3.3.1 Product/Service launches 325
15.1.3.3.2 Deals 325
15.1.3.4 MnM view 328
15.1.3.4.1 Key strengths 328
15.1.3.4.2 Strategic choices 328
15.1.3.4.3 Weaknesses & competitive threats 328
15.1.4 ILLUMINA, INC. 329
15.1.4.1 Business overview 329
15.1.4.2 Products/Services offered 330
15.1.4.3 Recent developments 331
15.1.4.3.1 Product/Service launches & approvals 331
15.1.4.3.2 Deals 332
15.1.4.3.3 Expansions 333
15.1.4.3.4 Other developments 334
15.1.4.4 MnM view 334
15.1.4.4.1 Key strengths 334
15.1.4.4.2 Strategic choices 334
15.1.4.4.3 Weaknesses & competitive threats 334
15.1.5 F. HOFFMANN-LA ROCHE LTD. 335
15.1.5.1 Business overview 335
15.1.5.2 Products/Services offered 336
15.1.5.3 Recent developments 337
15.1.5.3.1 Product/Service launches 337
15.1.5.3.2 Expansions 338
15.1.5.4 MnM view 338
15.1.5.4.1 Key strengths 338
15.1.5.4.2 Strategic choices 338
15.1.5.4.3 Weaknesses & competitive threats 338
15.1.6 QIAGEN N.V. 339
15.1.6.1 Business overview 339
15.1.6.2 Products/Services offered 340
15.1.6.3 Recent developments 341
15.1.6.3.1 Product/Service launches 341
15.1.6.3.2 Deals 342
15.1.6.3.3 Expansions 344
15.1.7 EXACT SCIENCES CORPORATION 345
15.1.7.1 Business overview 345
15.1.7.2 Products/Services offered 346
15.1.7.3 Recent developments 347
15.1.7.3.1 Product/Service launches 347
15.1.7.3.2 Deals 347
15.1.8 THERMO FISHER SCIENTIFIC INC. 349
15.1.8.1 Business overview 349
15.1.8.2 Products/Services offered 350
15.1.8.3 Recent developments 351
15.1.8.3.1 Product/Service launches 351
15.1.8.3.2 Deals 352
15.1.8.3.3 Expansions 353
15.1.9 GRAIL, INC. 354
15.1.9.1 Business overview 354
15.1.9.2 Products/Services offered 355
15.1.9.3 Recent developments 355
15.1.9.3.1 Product/Service approvals 355
15.1.9.3.2 Deals 355
15.1.10 BIO-RAD LABORATORIES, INC. 357
15.1.10.1 Business overview 357
15.1.10.2 Products/Services offered 359
15.1.10.3 Recent developments 359
15.1.10.3.1 Product/Service launches 359
15.1.10.3.2 Deals 360
15.1.11 SYSMEX CORPORATION 361
15.1.11.1 Business overview 361
15.1.11.2 Products/Services offered 362
15.1.11.3 Recent developments 363
15.1.11.3.1 Deals 363
15.1.11.3.2 Expansions 364
15.1.12 MDXHEALTH 365
15.1.12.1 Business overview 365
15.1.12.2 Products/Services offered 366
15.1.12.3 Recent developments 366
15.1.12.3.1 Deals 366
15.1.13 PERSONALIS, INC. 367
15.1.13.1 Business overview 367
15.1.13.2 Products/Services offered 368
15.1.13.3 Recent developments 369
15.1.13.3.1 Product/Service launches 369
15.1.13.3.2 Deals 369
15.1.14 THE MENARINI GROUP 371
15.1.14.1 Business overview 371
15.1.14.2 Products/Services offered 371
15.1.14.3 Recent developments 372
15.1.14.3.1 Product/Service launches 372
15.1.14.3.2 Deals 372
15.2 OTHER PLAYERS 373
15.2.1 NEOGENOMICS LABORATORIES 373
15.2.2 ANGLE PLC 374
15.2.3 LABCORP HOLDINGS INC. 375
15.2.4 BIO-TECHNE 376
15.2.5 MESA LABS, INC. 377
15.2.6 MEDGENOME 378
15.2.7 LUNGLIFE AI, INC. 379
15.2.8 STRAND 380
15.2.9 VORTEX BIOTECH HOLDINGS 381
15.2.10 FREENOME HOLDINGS, INC. 381
15.2.11 LUCENCE HEALTH INC. 382
15.2.12 NEW DAY DIAGNOSTICS, LLC 383
16 APPENDIX 384
16.1 DISCUSSION GUIDE 384
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 389
16.3 CUSTOMIZATION OPTIONS 391
16.4 RELATED REPORTS 391
16.5 AUTHOR DETAILS 392
LIST OF TABLES
TABLE 1 LIQUID BIOPSY MARKET: KEY DATA FROM PRIMARY SOURCES 43
TABLE 2 LIQUID BIOPSY MARKET: RISK ASSESSMENT ANALYSIS 52
TABLE 3 INCIDENCE OF CANCER CASES WORLDWIDE, BY TYPE (2022) 66
TABLE 4 PROJECTED INCREASE IN CANCER PATIENTS, 2022 VS.
2035 VS. 2050, BY REGION 66
TABLE 5 INDICATIVE SELLING PRICING TREND OF LIQUID BIOPSY PRODUCTS, 2023–2025 71
TABLE 6 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023–2025 71
TABLE 7 INDICATIVE SELLING PRICE TREND OF LIQUID BIOPSY PRODUCTS,
BY REGION, 2023–2025 72
TABLE 8 LIQUID BIOPSY MARKET: LIST OF KEY PATENTS 74
TABLE 9 IMPORT DATA (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION) 78
TABLE 10 EXPORT DATA (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION) 79
TABLE 11 LIQUID BIOPSY MARKET: ROLE IN THE ECOSYSTEM 80
TABLE 12 LIQUID BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS 81
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 83
TABLE 18 EUROPE: CLASSIFICATION OF DEVICES 85
TABLE 19 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 86
TABLE 20 LIQUID BIOPSY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 89
TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS (%) 92
TABLE 22 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS, BY RANK 93
TABLE 23 IMPLEMENTATION OF AI, BY KEY COMPANY & USE CASE 96
TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES 97
TABLE 25 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 101
TABLE 26 KEY ASSAY KITS CURRENTLY OFFERED 102
TABLE 27 LIQUID BIOPSY ASSAY KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 103
TABLE 28 NORTH AMERICA: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 104
TABLE 29 EUROPE: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 104
TABLE 30 ASIA PACIFIC: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 104
TABLE 31 LATIN AMERICA: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 105
TABLE 32 KEY INSTRUMENTS CURRENTLY OFFERED 106
TABLE 33 LIQUID BIOPSY INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 106
TABLE 34 NORTH AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 107
TABLE 35 EUROPE: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 107
TABLE 36 ASIA PACIFIC: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 107
TABLE 37 LATIN AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 108
TABLE 38 LIQUID BIOPSY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 109
TABLE 39 NORTH AMERICA: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 109
TABLE 40 EUROPE: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 109
TABLE 41 ASIA PACIFIC: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 110
TABLE 42 LATIN AMERICA: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 110
TABLE 43 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 112
TABLE 44 KEY CTDNA PRODUCTS CURRENTLY AVAILABLE 113
TABLE 45 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION,
2023–2030 (USD MILLION) 114
TABLE 46 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA,
BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 47 EUROPE: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA,
BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 48 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA,
BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 49 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA,
BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 50 KEY CELL-FREE DNA PRODUCTS CURRENTLY AVAILABLE 116
TABLE 51 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION,
2023–2030 (USD MILLION) 117
TABLE 52 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CELL-FREE DNA,
BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 53 EUROPE: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY,
2023–2030 (USD MILLION) 118
TABLE 54 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY,
2023–2030 (USD MILLION) 118
TABLE 55 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 56 KEY CTC PRODUCTS CURRENTLY AVAILABLE 120
TABLE 57 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION,
2023–2030 (USD MILLION) 120
TABLE 58 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS,
BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 59 EUROPE: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 60 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS,
BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 61 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS,
BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 62 KEY EXTRACELLULAR VESICLE PRODUCTS CURRENTLY AVAILABLE 122
TABLE 63 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION,
2023–2030 (USD MILLION) 122
TABLE 64 NORTH AMERICA: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES,
BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 65 EUROPE: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 66 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES,
BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 67 LATIN AMERICA: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES,
BY COUNTRY, 2023–2030 (USD MILLION) 124
TABLE 68 OTHER CIRCULATING BIOMARKER PRODUCTS CURRENTLY AVAILABLE 124
TABLE 69 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2023–2030 (USD MILLION) 125
TABLE 70 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 71 EUROPE: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS,
BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 72 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS,
BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 73 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 74 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 129
TABLE 75 KEY NGS-BASED PRODUCTS CURRENTLY AVAILABLE 130
TABLE 76 LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS,
BY REGION, 2023–2030 (USD MILLION) 130
TABLE 77 NORTH AMERICA: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 78 EUROPE: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 79 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 80 LATIN AMERICA: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 81 KEY PCR & MICROARRAY-BASED PRODUCTS CURRENTLY AVAILABLE 133
TABLE 82 LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2023–2030 (USD MILLION) 133
TABLE 83 NORTH AMERICA: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 84 EUROPE: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 85 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 86 LATIN AMERICA: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 87 LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 137
TABLE 88 GLOBAL CANCER INCIDENCE, 2022 VS. 2035 VS. 2045, BY REGION 138
TABLE 89 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION,
2023–2030 (USD MILLION) 139
TABLE 90 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 91 EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 92 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 93 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 94 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 141
TABLE 95 GLOBAL LUNG CANCER INCIDENCE, 2022 VS. 2035 VS. 2050 142
TABLE 96 KEY LIQUID BIOPSY PRODUCTS FOR LUNG CANCER 142
TABLE 97 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION,
2023–2030 (USD MILLION) 143
TABLE 98 NORTH AMERICA: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 99 EUROPE: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY,
2023–2030 (USD MILLION) 143
TABLE 100 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY,
2023–2030 (USD MILLION) 144
TABLE 101 LATIN AMERICA: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY,
2023–2030 (USD MILLION) 144
TABLE 102 GLOBAL BREAST CANCER INCIDENCE, 2022 VS. 2035 VS. 2050 145
TABLE 103 KEY LIQUID BIOPSY PRODUCTS FOR BREAST CANCER 146
TABLE 104 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION,
2023–2030 (USD MILLION) 146
TABLE 105 NORTH AMERICA: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 106 EUROPE: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY,
2023–2030 (USD MILLION) 147
TABLE 107 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY,
2023–2030 (USD MILLION) 147
TABLE 108 LATIN AMERICA: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 109 GLOBAL COLORECTAL CANCER INCIDENCE, 2022 VS. 2035 VS. 2050 149
TABLE 110 KEY LIQUID BIOPSY PRODUCTS FOR COLORECTAL CANCER 149
TABLE 111 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION,
2023–2030 (USD MILLION) 149
TABLE 112 NORTH AMERICA: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 113 EUROPE: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 114 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 115 LATIN AMERICA: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 116 GLOBAL PROSTATE CANCER INCIDENCE, 2022 VS. 2035 VS. 2050 152
TABLE 117 KEY LIQUID BIOPSY PRODUCTS FOR PROSTATE CANCER 152
TABLE 118 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION,
2023–2030 (USD MILLION) 152
TABLE 119 NORTH AMERICA: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 120 EUROPE: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY,
2023–2030 (USD MILLION) 153
TABLE 121 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 122 LATIN AMERICA: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 123 GLOBAL MELANOMA INCIDENCE, 2022 VS. 2035 VS. 2050 155
TABLE 124 LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION, 2023–2030 (USD MILLION) 155
TABLE 125 NORTH AMERICA: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY,
2023–2030 (USD MILLION) 156
TABLE 126 EUROPE: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY,
2023–2030 (USD MILLION) 156
TABLE 127 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY,
2023–2030 (USD MILLION) 156
TABLE 128 LATIN AMERICA: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY,
2023–2030 (USD MILLION) 157
TABLE 129 GLOBAL INCIDENCE OF OTHER CANCERS, 2022 VS. 2050 158
TABLE 130 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION,
2023–2030 (USD MILLION) 158
TABLE 131 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 132 EUROPE: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY,
2023–2030 (USD MILLION) 159
TABLE 133 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY,
2023–2030 (USD MILLION) 159
TABLE 134 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 135 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION,
2023–2030 (USD MILLION) 161
TABLE 136 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 161
TABLE 137 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 138 EUROPE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 139 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 140 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 141 KEY NIPT LIQUID BIOPSY PRODUCTS 164
TABLE 142 LIQUID BIOPSY MARKET FOR NIPT, BY REGION, 2023–2030 (USD MILLION) 164
TABLE 143 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY,
2023–2030 (USD MILLION) 164
TABLE 144 EUROPE: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY,
2023–2030 (USD MILLION) 165
TABLE 145 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY,
2023–2030 (USD MILLION) 165
TABLE 146 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY,
2023–2030 (USD MILLION) 165
TABLE 147 LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY REGION,
2023–2030 (USD MILLION) 166
TABLE 148 NORTH AMERICA: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION,
BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 149 EUROPE: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 150 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION,
BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 151 LATIN AMERICA: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION,
BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 152 LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION,
2023–2030 (USD MILLION) 169
TABLE 153 NORTH AMERICA: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING,
BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 154 EUROPE: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING,
BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 155 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING,
BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 156 LATIN AMERICA: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING,
BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 157 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 172
TABLE 158 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION,
2023–2030 (USD MILLION) 173
TABLE 159 NORTH AMERICA: LIQUID BIOPSY MARKET FOR THERAPY SELECTION,
BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 160 EUROPE: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY,
2023–2030 (USD MILLION) 174
TABLE 161 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 162 LATIN AMERICA: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 163 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION,
2023–2030 (USD MILLION) 176
TABLE 164 NORTH AMERICA: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING,
BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 165 EUROPE: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 166 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING,
BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 167 LATIN AMERICA: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING,
BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 168 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION,
2023–2030 (USD MILLION) 178
TABLE 169 NORTH AMERICA: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING,
BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 170 EUROPE: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 171 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING,
BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 172 LATIN AMERICA: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING,
BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 173 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION,
2023–2030 (USD MILLION) 181
TABLE 174 NORTH AMERICA: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING,
BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 175 EUROPE: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 176 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING,
BY COUNTRY, 2023–2030 (USD MILLION) 182
TABLE 177 LATIN AMERICA: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING,
BY COUNTRY, 2023–2030 (USD MILLION) 182
TABLE 178 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 184
TABLE 179 LIQUID BIOPSY SAMPLES & APPLICATIONS 184
TABLE 180 KEY BLOOD SAMPLE-BASED PRODUCTS CURRENTLY AVAILABLE 186
TABLE 181 LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY REGION,
2023–2030 (USD MILLION) 187
TABLE 182 NORTH AMERICA: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 187
TABLE 183 EUROPE: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY,
2023–2030 (USD MILLION) 187
TABLE 184 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY,
2023–2030 (USD MILLION) 188
TABLE 185 LATIN AMERICA: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 188
TABLE 186 LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY REGION,
2023–2030 (USD MILLION) 189
TABLE 187 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES,
BY COUNTRY, 2023–2030 (USD MILLION) 189
TABLE 188 EUROPE: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 189 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 190 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES,
BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 191 LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 192
TABLE 192 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION,
2023–2030 (USD MILLION) 193
TABLE 193 NORTH AMERICA: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES,
BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 194 EUROPE: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES,
BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 195 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES,
BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 196 LATIN AMERICA: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES,
BY COUNTRY, 2023–2030 (USD MILLION) 195
TABLE 197 LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES,
BY REGION, 2023–2030 (USD MILLION) 196
TABLE 198 NORTH AMERICA: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 199 EUROPE: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 200 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 201 LATIN AMERICA: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 198
TABLE 202 LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2023–2030 (USD MILLION) 199
TABLE 203 NORTH AMERICA: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 204 EUROPE: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS,
BY COUNTRY, 2023–2030 (USD MILLION) 200
TABLE 205 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS,
BY COUNTRY, 2023–2030 (USD MILLION) 200
TABLE 206 LATIN AMERICA: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 200
TABLE 207 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION,
2023–2030 (USD MILLION) 201
TABLE 208 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 209 EUROPE: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY,
2023–2030 (USD MILLION) 202
TABLE 210 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 211 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 203
TABLE 212 LIQUID BIOPSY MARKET, BY REGION, 2023–2030 (USD MILLION) 205
TABLE 213 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY CANCER TYPE,
2022 VS. 2050 206
TABLE 214 NORTH AMERICA: MACROECONOMIC INDICATORS 207
TABLE 215 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 208
TABLE 216 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 208
TABLE 217 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 208
TABLE 218 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 209
TABLE 219 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 209
TABLE 220 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 209
TABLE 221 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 210
TABLE 222 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 210
TABLE 223 NORTH AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 210
TABLE 224 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER,
2023–2030 (USD MILLION) 211
TABLE 225 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 212
TABLE 226 US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 212
TABLE 227 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 213
TABLE 228 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 213
TABLE 229 US: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 213
TABLE 230 US: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 214
TABLE 231 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 214
TABLE 232 US: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 214
TABLE 233 US: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 215
TABLE 234 US: TOTAL NUMBER OF WOMEN WHO UNDERGO NIPT TESTING,
2023–2030 (MILLION UNITS) 215
TABLE 235 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 216
TABLE 236 CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 217
TABLE 237 CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 217
TABLE 238 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 217
TABLE 239 CANADA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 218
TABLE 240 CANADA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 218
TABLE 241 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 219
TABLE 242 CANADA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 219
TABLE 243 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 219
TABLE 244 EUROPE: MACROECONOMIC INDICATORS 221
TABLE 245 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 221
TABLE 246 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 221
TABLE 247 EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 222
TABLE 248 EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 222
TABLE 249 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 222
TABLE 250 EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 223
TABLE 251 EUROPE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 223
TABLE 252 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 224
TABLE 253 EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 224
TABLE 254 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 224
TABLE 255 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 226
TABLE 256 GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 226
TABLE 257 GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 226
TABLE 258 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 227
TABLE 259 GERMANY: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 227
TABLE 260 GERMANY: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 227
TABLE 261 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 228
TABLE 262 GERMANY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 228
TABLE 263 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 228
TABLE 264 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 230
TABLE 265 UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 230
TABLE 266 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 230
TABLE 267 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 231
TABLE 268 UK: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 231
TABLE 269 UK: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 231
TABLE 270 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 232
TABLE 271 UK: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 232
TABLE 272 UK: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 232
TABLE 273 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 233
TABLE 274 FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 234
TABLE 275 FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 234
TABLE 276 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 234
TABLE 277 FRANCE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 235
TABLE 278 FRANCE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 235
TABLE 279 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 236
TABLE 280 FRANCE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 236
TABLE 281 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 236
TABLE 282 ITALY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 237
TABLE 283 ITALY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 238
TABLE 284 ITALY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 238
TABLE 285 ITALY: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 238
TABLE 286 ITALY: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 239
TABLE 287 ITALY: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 239
TABLE 288 ITALY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 240
TABLE 289 ITALY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 240
TABLE 290 ITALY: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 240
TABLE 291 SPAIN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 242
TABLE 292 SPAIN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 242
TABLE 293 SPAIN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 242
TABLE 294 SPAIN: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 243
TABLE 295 SPAIN: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 243
TABLE 296 SPAIN: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 243
TABLE 297 SPAIN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 244
TABLE 298 SPAIN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 244
TABLE 299 SPAIN: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 244
TABLE 300 REST OF EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 246
TABLE 301 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 246
TABLE 302 REST OF EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 246
TABLE 303 REST OF EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 247
TABLE 304 REST OF EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 247
TABLE 305 REST OF EUROPE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 247
TABLE 306 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 248
TABLE 307 REST OF EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 248
TABLE 308 REST OF EUROPE: LIQUID BIOPSY MARKET, BY END USER,
2023–2030 (USD MILLION) 248
TABLE 309 ASIA PACIFIC: MACROECONOMIC INDICATORS 250
TABLE 310 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 251
TABLE 311 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 251
TABLE 312 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 251
TABLE 313 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 252
TABLE 314 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 252
TABLE 315 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 252
TABLE 316 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 253
TABLE 317 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 253
TABLE 318 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 253
TABLE 319 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 254
TABLE 320 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 255
TABLE 321 CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 255
TABLE 322 CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 256
TABLE 323 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 256
TABLE 324 CHINA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 256
TABLE 325 CHINA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 257
TABLE 326 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 257
TABLE 327 CHINA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 257
TABLE 328 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 258
TABLE 329 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 259
TABLE 330 JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 259
TABLE 331 JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 259
TABLE 332 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 260
TABLE 333 JAPAN: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 260
TABLE 334 JAPAN: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 260
TABLE 335 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 261
TABLE 336 JAPAN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 261
TABLE 337 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 261
TABLE 338 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 263
TABLE 339 INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 263
TABLE 340 INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 263
TABLE 341 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 264
TABLE 342 INDIA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 264
TABLE 343 INDIA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 264
TABLE 344 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 265
TABLE 345 INDIA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 265
TABLE 346 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 265
TABLE 347 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 267
TABLE 348 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 267
TABLE 349 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 267
TABLE 350 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 268
TABLE 351 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 268
TABLE 352 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 268
TABLE 353 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 269
TABLE 354 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 269
TABLE 355 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER,
2023–2030 (USD MILLION) 269
TABLE 356 LATIN AMERICA: MACROECONOMIC INDICATORS 271
TABLE 357 LATIN AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 271
TABLE 358 LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 272
TABLE 359 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 272
TABLE 360 LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 272
TABLE 361 LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 273
TABLE 362 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 273
TABLE 363 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 273
TABLE 364 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 274
TABLE 365 LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 274
TABLE 366 LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER,
2023–2030 (USD MILLION) 274
TABLE 367 BRAZIL: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 275
TABLE 368 BRAZIL: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 276
TABLE 369 BRAZIL: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 276
TABLE 370 BRAZIL: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 276
TABLE 371 BRAZIL: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 277
TABLE 372 BRAZIL: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 277
TABLE 373 BRAZIL: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 278
TABLE 374 BRAZIL: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 278
TABLE 375 BRAZIL: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 278
TABLE 376 MEXICO: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 279
TABLE 377 MEXICO: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2023–2030 (USD MILLION) 280
TABLE 378 MEXICO: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 280
TABLE 379 MEXICO: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 280
TABLE 380 MEXICO: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 281
TABLE 381 MEXICO: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 281
TABLE 382 MEXICO: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2023–2030 (USD MILLION) 282
TABLE 383 MEXICO: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 282
TABLE 384 MEXICO: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 282
TABLE 385 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 283
TABLE 386 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 284
TABLE 387 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 284
TABLE 388 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 284
TABLE 389 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 285
TABLE 390 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 285
TABLE 391 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 286
TABLE 392 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 286
TABLE 393 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER,
2023–2030 (USD MILLION) 286
TABLE 394 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 288
TABLE 395 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 288
TABLE 396 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 289
TABLE 397 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 289
TABLE 398 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 289
TABLE 399 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 290
TABLE 400 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 290
TABLE 401 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 291
TABLE 402 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 291
TABLE 403 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY END USER,
2023–2030 (USD MILLION) 291
TABLE 404 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN LIQUID BIOPSY MARKET, JANUARY 2021−JUNE 2025 292
TABLE 405 LIQUID BIOPSY MARKET: DEGREE OF COMPETITION 295
TABLE 406 LIQUID BIOPSY MARKET: REGION FOOTPRINT 300
TABLE 407 LIQUID BIOPSY MARKET: PRODUCT & SERVICE FOOTPRINT 300
TABLE 408 LIQUID BIOPSY MARKET: APPLICATION FOOTPRINT 301
TABLE 409 LIQUID BIOPSY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 303
TABLE 410 LIQUID BIOPSY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT & SERVICE 303
TABLE 411 LIQUID BIOPSY MARKET: COMPETITIVE BENCHMARKING OF
KEY STARTUPS/SMES, BY REGION 304
TABLE 412 LIQUID BIOPSY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021–JUNE 2025 307
TABLE 413 LIQUID BIOPSY MARKET: DEALS, JANUARY 2021–JUNE 2025 308
TABLE 414 LIQUID BIOPSY MARKET: EXPANSIONS, JANUARY 2021–JUNE 2025 309
TABLE 415 NATERA, INC.: COMPANY OVERVIEW 311
TABLE 416 NATERA, INC.: PRODUCTS/SERVICES OFFERED 312
TABLE 417 NATERA, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–JUNE 2025 313
TABLE 418 NATERA, INC.: DEALS, JANUARY 2021−JUNE 2025 314
TABLE 419 NATERA, INC.: OTHER DEVELOPMENTS, JANUARY 2021– JUNE 2025 314
TABLE 420 GUARDANT HEALTH: COMPANY OVERVIEW 316
TABLE 421 GUARDANT HEALTH: PRODUCTS/SERVICES OFFERED 317
TABLE 422 GUARDANT HEALTH: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−JUNE 2025 318
TABLE 423 GUARDANT HEALTH: DEALS, JANUARY 2021−JUNE 2025 320
TABLE 424 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 323
TABLE 425 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES OFFERED 324
TABLE 426 MYRIAD GENETICS, INC.: PRODUCT/SERVICE LAUNCHES,
JANUARY 2021−JUNE 2025 325
TABLE 427 MYRIAD GENETICS, INC.: DEALS, JANUARY 2021−JUNE 2025 325
TABLE 428 ILLUMINA, INC.: COMPANY OVERVIEW 329
TABLE 429 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED 330
TABLE 430 ILLUMINA, INC.:PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021−JUNE 2025 331
TABLE 431 ILLUMINA, INC.: DEALS, JANUARY 2021−JUNE 2025 332
TABLE 432 ILLUMINA, INC.: EXPANSIONS, JANUARY 2021−JUNE 2025 333
TABLE 433 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2021−JUNE 2025 334
TABLE 434 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 335
TABLE 435 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 336
TABLE 436 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES,
JANUARY 2021−JUNE 2025 337
TABLE 437 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021−JUNE 2025 338
TABLE 438 QIAGEN N.V.: COMPANY OVERVIEW 339
TABLE 439 QIAGEN N.V.: PRODUCTS/SERVICES OFFERED 340
TABLE 440 QIAGEN N.V.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025 341
TABLE 441 QIAGEN N.V.: DEALS, JANUARY 2021−JUNE 2025 342
TABLE 442 QIAGEN: EXPANSIONS, JANUARY 2021−JUNE 2025 344
TABLE 443 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW 345
TABLE 444 EXACT SCIENCES CORPORATION: PRODUCTS/SERVICES OFFERED 346
TABLE 445 EXACT SCIENCES CORPORATION: PRODUCT/SERVICE LAUNCHES,
JANUARY 2021−JUNE 2025 347
TABLE 446 EXACT SCIENCES CORPORATION: DEALS, JANUARY 2021−JUNE 2025 347
TABLE 447 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 349
TABLE 448 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 350
TABLE 449 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES,
JANUARY 2021−JUNE 2025 351
TABLE 450 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021−JUNE 2025 352
TABLE 451 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021−JUNE 2025 353
TABLE 452 GRAIL, INC.: COMPANY OVERVIEW 354
TABLE 453 GRAIL, INC.: PRODUCTS/SERVICES OFFERED 355
TABLE 454 GRAIL, INC.: PRODUCT/SERVICE APPROVALS, JANUARY 2021−JUNE 2025 355
TABLE 455 GRAIL, INC.: DEALS, JANUARY 2021−JUNE 2025 355
TABLE 456 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 357
TABLE 457 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 359
TABLE 458 BIO-RAD LABORATORIES, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025 359
TABLE 459 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021−JUNE 2025 360
TABLE 460 SYSMEX CORPORATION: COMPANY OVERVIEW 361
TABLE 461 SYSMEX CORPORATION: PRODUCTS/SERVICES OFFERED 362
TABLE 462 SYSMEX CORPORATION: DEALS, JANUARY 2021−JUNE 2025 363
TABLE 463 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2021−JUNE 2025 364
TABLE 464 MDXHEALTH: COMPANY OVERVIEW 365
TABLE 465 MDXHEALTH: PRODUCTS/SERVICES OFFERED 366
TABLE 466 MDXHEALTH: DEALS, JANUARY 2021−JUNE 2025 366
TABLE 467 PERSONALIS, INC.: COMPANY OVERVIEW 367
TABLE 468 PERSONALIS, INC.: PRODUCTS/SERVICES OFFERED 368
TABLE 469 PERSONALIS, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025 369
TABLE 470 PERSONALIS, INC.: DEALS, JANUARY 2021−JUNE 2025 369
TABLE 471 THE MENARINI GROUP: COMPANY OVERVIEW 371
TABLE 472 THE MENARINI GROUP: PRODUCTS/SERVICES OFFERED 371
TABLE 473 THE MENARINI GROUP: PRODUCT/SERVICE LAUNCHES,
JANUARY 2021−JUNE 2025 372
TABLE 474 THE MENARINI GROUP: DEALS, JANUARY 2021−JUNE 2025 372
TABLE 475 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW 373
TABLE 476 ANGLE PLC: COMPANY OVERVIEW 374
TABLE 477 LABCORP HOLDINGS INC.: COMPANY OVERVIEW 375
TABLE 478 BIO-TECHNE: COMPANY OVERVIEW 376
TABLE 479 MESA LABS, INC.: COMPANY OVERVIEW 377
TABLE 480 MEDGENOME: COMPANY OVERVIEW 378
TABLE 481 LUNGLIFE AI, INC.: COMPANY OVERVIEW 379
TABLE 482 STRAND: COMPANY OVERVIEW 380
TABLE 483 VORTEX BIOTECH HOLDINGS: COMPANY OVERVIEW 381
TABLE 484 FREENOME HOLDINGS, INC.: COMPANY OVERVIEW 381
TABLE 485 LUCENCE HEALTH INC.: COMPANY OVERVIEW 382
TABLE 486 NEW DAY DIAGNOSTICS, LLC: COMPANY OVERVIEW 383
LIST OF FIGURES
FIGURE 1 LIQUID BIOPSY MARKET SEGMENTATION & REGIONAL SCOPE 36
FIGURE 2 LIQUID BIOPSY MARKET: RESEARCH DESIGN METHODOLOGY 40
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 45
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 46
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 47
FIGURE 6 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 48
FIGURE 7 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH 49
FIGURE 8 DATA TRIANGULATION METHODOLOGY 50
FIGURE 9 LIQUID BIOPSY MARKET: PARAMETRIC ASSUMPTIONS ANALYSIS 51
FIGURE 10 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION) 53
FIGURE 11 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE,
2025 VS. 2030 (USD MILLION) 54
FIGURE 12 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 54
FIGURE 13 LIQUID BIOPSY MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 55
FIGURE 14 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2025 VS. 2030 (USD MILLION) 56
FIGURE 15 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION) 57
FIGURE 16 LIQUID BIOPSY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 57
FIGURE 17 LIQUID BIOPSY MARKET, BY REGION, 2025 VS. 2030 (USD MILLION) 58
FIGURE 18 INCREASING INCIDENCE OF CANCER AND ADVANCES IN
LIQUID BIOPSY TECHNOLOGIES TO PROPEL MARKET 59
FIGURE 19 ASSAY KITS SEGMENT IS EXPECTED TO DOMINATE
MARKET DURING FORECAST PERIOD 60
FIGURE 20 CIRCULATING TUMOR DNA SEGMENT TO DOMINATE
MARKET DURING FORECAST PERIOD 60
FIGURE 21 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT
TO DOMINATE MARKET DURING FORECAST PERIOD 61
FIGURE 22 CANCER APPLICATIONS SEGMENT TO DOMINATE MARKET
DURING FORECAST PERIOD 61
FIGURE 23 THERAPY SELECTION SEGMENT TO DOMINATE MARKET
DURING FORECAST PERIOD 62
FIGURE 24 BLOOD SAMPLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 62
FIGURE 25 REFERENCE LABORATORIES SEGMENT TO DOMINATE MARKET
DURING FORECAST PERIOD 63
FIGURE 26 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 63
FIGURE 27 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 64
FIGURE 28 PATENT ANALYSIS FOR LIQUID BIOPSY (JANUARY 2015–DECEMBER 2024) 73
FIGURE 29 VALUE CHAIN ANALYSIS OF LIQUID BIOPSY MARKET: MAJOR VALUE-ADDED DURING MANUFACTURING & ASSEMBLY PHASES 76
FIGURE 30 LIQUID BIOPSY MARKET: SUPPLY CHAIN ANALYSIS 77
FIGURE 31 LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS 80
FIGURE 32 LIQUID BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS 81
FIGURE 33 LIQUID BIOPSY MARKET: TRENDS/DISRUPTIONS
IMPACTING CUSTOMERS’ BUSINESSES 91
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
FOR LIQUID BIOPSY PRODUCTS 92
FIGURE 35 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS 92
FIGURE 36 NUMBER OF DEALS & FUNDING ACTIVITIES IN LIQUID BIOPSY MARKET 93
FIGURE 37 MARKET POTENTIAL OF AI IN LIQUID BIOPSY MARKET 95
FIGURE 38 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT 207
FIGURE 39 ASIA PACIFIC: LIQUID BIOPSY MARKET SNAPSHOT 250
FIGURE 40 REVENUE ANALYSIS OF LEADING FIVE PLAYERS, 2022−2024 294
FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS (2024) 295
FIGURE 42 LIQUID BIOPSY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 298
FIGURE 43 LIQUID BIOPSY MARKET: COMPANY FOOTPRINT 299
FIGURE 44 LIQUID BIOPSY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 302
FIGURE 45 EV/EBITDA OF KEY VENDORS 305
FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 305
FIGURE 47 BRAND COMPARISON: PCR-BASED LIQUID BIOPSY ASSAYS 306
FIGURE 48 NATERA, INC.: COMPANY SNAPSHOT (2024) 312
FIGURE 49 GUARDANT HEALTH: COMPANY SNAPSHOT (2024) 317
FIGURE 50 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2024) 324
FIGURE 51 ILLUMINA, INC.: COMPANY SNAPSHOT (2024) 330
FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 336
FIGURE 53 QIAGEN N.V.: COMPANY SNAPSHOT (2024) 340
FIGURE 54 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2024) 346
FIGURE 55 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 350
FIGURE 56 GRAIL, INC.: COMPANY SNAPSHOT (2024) 354
FIGURE 57 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024) 358
FIGURE 58 SYSMEX CORPORATION: COMPANY SNAPSHOT (2024) 362
FIGURE 59 MDXHEALTH: COMPANY SNAPSHOT (2024) 365
FIGURE 60 PERSONALIS, INC.: COMPANY SNAPSHOT (2024) 368
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11